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ABBREVIATIONS 
ABCA-1 Adenosine triphosphate Binding Cassette Transporter-1 
ACTG AIDS Clinical Trial Group 
ART Antiretroviral therapy 
BMI Body Mass Index 
CAD Coronary Arterial Disease 
CCL-2 Chemokine (C–C) motif ligand-2 
CD Cluster Differentiation 
CHD Coronary Heart Disease 
CRP C-Reactive Protein 
CVD Cardiovascular diseases 
ECM Extracellular matrix 
FGF Fibroblast Growth Factor 
FRAM Fat Redistribution And Metabolic changes in HIV infection 
HAART Highly Active Antiretroviral Treatment 
HBV Hepatitis B Virus 
HCV Hepatitis C Virus 
HDL High Density Lipoprotein 
HIV Human Immunodeficiency Virus 
HR Hazard Ratio 
hsCRP high sensitivity CRP 
IFN Interferon 
IL Interleukin 
IMT Intimal Medial Thickness 
LDL Low Density Lipoprotein 
MCP-1 Monocyte Chemotactic Protein-1 
MESA Multi-Ethnic Study of Atherosclerosis 
MI Myocardial Infarction 
mtDNA mitochondrial Deoxyribonucleic acid 
NACO National AIDS Control Organization 
NNRTI Non-nucleoside Reverse Transcriptase Inhibitors 
NRTI Nucleoside Reverse Transcriptase Inhibitors 
PDGF Platelet Derived Growth Factor 
PI Protease Inhibitor 
PPAR Peroxisome Proliferator Activated Receptor 
TGF Transforming Growth Factor 
TNF Tumor Necrosis Factor 
UNAIDS Joint United Nations Programme on HIV/AIDS 
VCAM Vascular Cell Adhesion Molecule 
WHO  World Health Organisation 
AIMS AND OBJECTIVES 
HIV infection and the use of antiretroviral treatment may be a risk factor 
for premature atherosclerosis development, hence for increased cardiovascular 
and cerebrovascular morbidities and mortalities in these groups. Our aim was, 
• To measure the carotid intimal-medial thickness in HIV infected subjects 
with and without antiretroviral therapy 
To compare intimal-media thickness (IMT) of the carotid artery between HIV-
infected subjects (without and with antiretroviral therapy) and controls. 
INTRODUCTION 
Human immunodeficiency virus (HIV) infection/Acquired 
Immunodeficiency Syndrome is a global pandemic. According to WHO- 
UNAIDS, 33.2 million individuals were living with HIV infection according to  
2007statistics (1). As per the provisional HIV estimate of 2008-09, there are an 
estimated 22.7 lakhs people living with HIV/AIDS in India. The HIV 
prevalence rate in the country is 0.29 percent (2008-09) (2).NACO launched 
Highly Active Anti Retroviral Therapy (HAART) on April 2004 in India. 
Currently there are 285 ART centres in India, and about 3.6 lakhs patients are 
on ART (august 2010) (3). 
With the introduction of antiretroviral therapy (ART), the survival of HIV-
infected individuals has dramatically improved and there are significant 
reduction in the HIV-related morbidity and mortality (4, 5, 6). 
In the context of declining rates of HIV-related death, proportions of HIV 
infected patients dying of other causes have increased. In United States, the 
proportion of deaths among HIV-infected patients due to non–HIV-related 
causes increased from19.8% to 26.3% between 1999 and 2006 (7). 
Cardiovascular and the cerebrovascular diseases were leading among the 
causes. However, it is controversial whether HIV infection contributes to 
accelerated atherosclerosis independent of traditional CVD risk factors. 
So, there is an urgent need to determine whether people with HIV infection 
are at an increased risk for atherosclerosis. Various lipid dyscrasias are well 
documented in HIV infected patients with ART therapy. In addition to lipid 
dyscrasias, patients with HIV infection also experience metabolic abnormalities 
including insulin resistance, visceral adiposity, and chronic immune activation. 
However, the relation between the metabolic abnormalities and increased risk of 
atherosclerosis is not well established.  
FRAM (Fat Redistribution And Metabolic Change in HIV Infection) study 
(8)
 shows that antiretroviral treatment and HIV infection contributes to 
accelerated atherosclerosis independent of traditional cardiovascular risk 
factors. But few other studies have varying results. 
Measurement of carotid artery intimal-medial thickness (IMT) with high 
resolution B-mode ultrasound is a well-accepted, non-invasive method of 
assessing atherosclerosis and tracking its progression (9). Carotid IMT 
measurements correlate well with pathological measurements and are potent 
predictors of myocardial infarction and stroke. 
In our study, we evaluated the IMT of the carotid vessels to determine 
premature atherosclerotic lesions using   an ultrasound colour-Doppler technique 
in HIV negative, HIV-infected subjects. This study was designed to identify the 
role of ART therapy and HIV infection on the risk of development of 
subclinical atherosclerosis by comparing the carotid intimal medial thickness. 
  
 
REVIEW OF LITERATURE 
Cardiovascular Complications Of HIV Infection And Antiretroviral Drugs: 
As per the provisional HIV estimate of 2008-09, there are an estimated 
22.7 lakhs people living with HIV/AIDS in India (1). NACO launched Highly 
Active Anti Retroviral Therapy (HAART) on April 2004 in India. Currently 
there are 285 ART centres in India, and about 3.6 lakhs (16%) patients are on 
ART (august 2010) (3). 
Epidemiology of Cardiovascular Disease in HIV-Infected Persons 
In the context of declining rates of HIV-related death, proportions of HIV 
infected Patients dying of other causes have increased. For example, a death 
certificate study in New York City (USA) showed that the proportion of deaths 
among HIV-infected patients between 1999 to 2006, reflecting mortality 
resulting from non-HIV-related causes increased from19.8% to 26.3% mainly  
from cardiovascular disease (CVD), substance abuse, and non–AIDS-defining 
cancers (4). Among individuals aged 55 years or older, CVD was the leading 
cause of death. Numerous studies have indicated the increased risk of 
myocardial infarction (MI) in HIV populations, with HIV infection considered 
at least a partial CVD risk factor in these studies. Klein and colleagues reported 
hospital-admission rates for coronary heart disease (CHD) in HIV-infected 
versus HIV uninfected populations of 6.5 versus3.8 per 1000 person-years (10) 
and 4.5 versus 2.9 per 1000 person-years in updated analyses with further 
follow-up time (11) respectively. 
Figure 1 Myocardial infarction rates among HIV infected versus HIV uninfected 




Currier and colleagues found a higher risk of coronary artery disease 
(CAD) admissions among younger HIV-infected than among HIV-uninfected 
patients(12); Triant and colleagues found a 75% increase in risk of MI admissions 
in HIV-infected patients(13); and Obel and colleagues found a 39% to 112% 
increased risk of CAD admissions in HIV-infected patients(14). The study by 
Triant and colleagues was performed using data from a Massachusetts 
administrative hospital database including 3851 HIV-infected patients and more 
than 1 million HIVuninfected patients from 1996 to 2004.The mean MI rates 
were 11.13 versus 6.98 per 1000 person-years respectively. MI rates were 
higher in HIV-infected patients in all age groups, with very high rates in older 
patients. These investigators have also reported that levels of the acute-phase 
reactant C-reactive protein (CRP) were predictive of risk of MI in HIV-infected 
patients, despite the fact that CRP levels generally are non-specifically elevated 
in HIV Infection (15). These findings underscore the need to determine why the 
rates of CVD are higher in HIV-infected than –uninfected individuals. 
Understanding the relative contributions of host, virus, and antiretroviral 
therapy to risk of CVD in HIV infection will help in the development of 
strategies for prevention and treatment. 
Pathophysiology Of Atherosclerosis In General: (16) 
The mechanism of atherosclerosis is explained by the response to injury 
hypothesis. Endothelial cell injury is the corner stone of the response to-injury 
hypothesis. Endothelial loss due to any kind of injury—induced experimentally 
by mechanical denudation, hemodynamic forces, immune complex deposition, 
irradiation, or chemicals—results in intimal thickening; in the presence of high-
lipid diets, typical atheromas ensue. However, early human lesions begin at sites 
of morphologically intact endothelium. Thus, endothelial dysfunction underlies 
human atherosclerosis; in this setting, dysfunctional endothelial cells show 
increased endothelial permeability, enhanced leukocyte adhesion, and altered 
gene expression. 
The specific pathways and factors contributing to endothelial cell 
dysfunction in early atherosclerosis are not completely understood; etiologic 
culprits include hypertension, hyperlipidemia, and toxins from cigarette smoke. 
Inflammatory cytokines (e.g., tumour necrosis factor [TNF]) can also stimulate 
pro-atherogenic patterns of endothelial cell gene expression. However, the two 
most important causes of endothelial dysfunction are hemodynamic 
disturbances and hypercholesterolemia. 
Role Of Lipids In Atherosclerosis:  
Lipids are typically transported in the bloodstream bound to specific 
apoproteins (forming lipoprotein complexes). Dyslipoproteinemias can result 
from mutations that alter the apoproteins or the lipoprotein receptors on cells, or 
from other disorders that affect the circulating levels of lipids (e.g., nephrotic 
syndrome, alcoholism, hypothyroidism, or diabetes mellitus). Common 
lipoprotein abnormalities in the general population (indeed, present in many 
myocardial infarction survivors) includes, 
• Increased LDL cholesterol levels,  
• Decreased HDL cholesterol levels, and  
• Increased levels of the abnormal lipoprotein (a). 
The mechanisms by which hyperlipidemia contributes to atherogenesis 
include the following: 
Chronic hyperlipidemia, particularly hypercholesterolemia, can directly 
impair endothelial cell function by increasing local oxygen free radical 
production; oxygen free radicals can injure tissues and accelerate nitric oxide 
decay, reducing its vasodilator activity. With chronic hyperlipidemia, 
lipoproteins accumulate within the intima. These lipids are oxidized through the 
action of oxygen free radicals locally generated by macrophages or endothelial 
cells. Oxidized LDL is ingested by macrophages through a scavenger receptor, 
distinct from the LDL receptor, and accumulates in phagocytes, which are then 
called foam cells. In addition, oxidized LDL stimulates the release of growth 
factors, cytokines, and chemokines by endothelial cells and macrophages that 
increase monocyte recruitment into lesions. Finally, oxidized LDL is cytotoxic 
to endothelial cells and smooth muscle cells and can induce endothelial cell 
dysfunction. The importance of oxidized LDL in atherogenesis is suggested by 
the fact that it accumulates within macrophages in all stages of plaque 
formation. 
Monocytes transform into macrophages and avidly engulf lipoproteins 
including oxidized LDL. Monocyte recruitment and differentiation into 
macrophages (and ultimately into foam cells) is theoretically protective, because 
these cells remove potentially harmful lipid particles. However, the oxidized 
LDL augments macrophage activation and cytokine production (e.g., TNF). 
This further increases leukocyte adhesion and production of chemokines (e.g., 
MCP-1; monocyte chemotactic protein-1), creating a stimulus for recruitment of 
additional mononuclear inflammatory cells. Activated macrophages also 
produce reactive oxygen species that aggravate LDL oxidation and elaborate 
growth factors that drive smooth muscle cell proliferation. 
T lymphocytes recruited to the intima interact with the macrophages and 
can generate a chronic inflammatory state. It is not clear whether the T cells are 
responding to specific antigens (e.g., bacterial or viral antigens, heat-shock 
proteins, or modified arterial wall constituents and lipoproteins) or are non-
specifically activated by the local inflammatory milieu. Nevertheless, activated 
T cells in the growing intimal lesions elaborate inflammatory cytokines (e.g., 
IFNγ) which can stimulate macrophages as well as endothelial cells and smooth 
muscle cells. As a consequence of the chronic inflammatory state, activated 
leukocytes and vascular wall cells release growth factors that promote smooth 
muscle cell proliferation and ECM synthesis. 
Role Of Inflammation In Atherosclerosis:  
Inflammatory cells and pathways contribute to the initiation, progression, 
and complications of atherosclerotic lesions. Although normal vessels do not 
bind inflammatory cells, early in atherogenesis, dysfunctional arterial 
endothelial cells express adhesion molecules that encourage leukocyte adhesion; 
vascular cell adhesion molecule 1 (VCAM-1), in particular, binds monocytes 
and T cells. After these cells adhere to the endothelium, they migrate into the 
intima under the influence of locally produced chemokines. 
Smooth Muscle Proliferation:  
Intimal smooth muscle cell proliferation and ECM deposition convert a 
fatty streak, the earliest lesion, into a mature atheroma and contribute to the 
progressive growth of atherosclerotic lesions (The intimal smooth muscle cells 
may be recruited from circulating precursors and they have a proliferative and 
synthetic phenotype distinct from the underlying medial smooth muscle cells). 
Several growth factors are implicated in smooth muscle cell proliferation and 
ECM synthesis, including PDGF (released by locally adherent platelets, as well 
as macrophages, endothelial cells, and smooth muscle cells), FGF, and TGF-α. 
The recruited smooth muscle cells synthesize ECM (notably collagen) that 
stabilizes atherosclerotic plaques. However, activated inflammatory cells in 
atheromas can cause intimal smooth muscle cell apoptosis, and also increase 
ECM catabolism resulting in unstable plaques.  
  
Factors Behind The Accelerated Atherosclerosis In HIV Patients: 
Host Factors 
Traditional CVD risk factors, as well as HIV infection and its treatment, 
contribute to the risk of CVD in HIV-infected individuals. The risk of MI in 
both HIV-infected and -uninfected populations is increased in a similar manner 
by the risk factors of increasing age, male sex, diabetes, smoking, and 
hypertension(17). The prevalence of some risk factors may be higher in HIV-
infected populations. A recent analysis of modifiable risk factors and death in 
the D: A: D (Data Collection on Adverse Events of Anti-HIV Drugs) study (18) 
showed that smoking (rate ratio, 1.20), hypertension (rate ratio, 1.53), and 
diabetes (rate ratio, 1.83) were independently associated with risk of death 
during treatment for HIV infection (19). Smoking is common in many HIV-
infected populations, and programs aimed at cessation have thus far been 
largely unsuccessful (20). 
Greater attention needs to be given to smoking and other modifiable CVD 
risk factors in HIVinfected patients. Increased carotid artery intima-media 
thickness (IMT), a marker for subclinical atherosclerosis, is associated with 
increased risk of MI. An analysis from the FRAM (Fat Redistribution And 
Metabolism) study showed that HIV infection was associated with statistically 
significant increase in internal carotid (0.15 mm; P < .001) and common carotid 
(0.033 mm; P < .01) IMT compared with IMT values for a large population of 
HIV-uninfected persons(21). Because most HIV infected patients in the FRAM 
study were receiving antiretroviral therapy, any potential effect of anti retroviral 
therapy on this finding is uncertain. Other traditional risk factors associate with 
increased IMT in the FRAM patients were male sex, current and past smoking, 
diabetes, age per 10-year increase, systolic blood pressure increase, and total 
cholesterol level increase.   High-density lipoprotein (HDL) cholesterol level 
increase was associated with a statistically significant reduction in IMT. 
Virus Factors 
The SMART (Strategies for Management of Antiretroviral Therapy) study 
examined the potential for reducing antiretroviral therapy toxicity by limiting 
time on treatment, with 5472 patients with CD4+ counts higher than 350 
cells/µL randomly assigned to a treatment-interruption plan (termed drug-
conservation strategy) or to continuous treatment (viral-suppression strategy). 
The drug-conservation strategy increased risk over the viral suppression 
strategy of opportunistic disease or death (rates, 3.4% vs1.3%, respectively; 
hazard ratio [HR],2.6) and of CVD, renal, or liver events(rates, 1.8% vs 1.1%, 
respectively; HR,1.7) (22). The study brought into focus the importance of 
serious non–AIDS-related events among patients without viral suppression on 
antiretroviral therapy. Subsequent analysis did not find an association between 
viral load and risk of CVD, but confirmed increased risk of CVD among 
patients who discontinued antiretroviral therapy. 
A number of mechanisms have been proposed to explain how HIV 
infection might contribute to atherosclerosis. 
1. HIV has been reported to infect smooth muscle cells in vitro and in vivo. 
2. HIV increases secretion of Monocyte chemo attractant molecules like 
CCL2, and MCP-1. This facilitates development of foam cells (23). 
3. Macrophages, which play a pivotal role in atherosclerosis, are also hosts 
for HIV. 
4. It is proved that there is impairment of cholesterol efflux (reverse 
cholesterol transport) in HIV-infected macrophages.  HIV Nef protein is 
critical for cholesterol efflux impairment. It specifically targets adenosine 
triphosphate binding cassette (ABCA-1) transporter -dependent 
cholesterol efflux and also down-regulates ABCA1. Nef alters 
intracellular distribution of ABCA1. HIV-infected macrophages 
transform into foam cells and they are found in atherosclerotic plaques of 
HIV-infected patients. Active cholesterol efflux reduces infectivity of 
HIV virions. These pathological effects of HIV may initiate and 
accelerate the plaque formation in vessel walls (24).  
5. HIV tat protein interaction with signal transduction pathways that lead to 
increased expression of vascular endothelial growth factors and platelet 
activating factor; and HIV membrane micro particles inhibit the 
endothelial nitric oxide synthase expression. 
6. This effect of Nef inhibition on the ABCA-1transporter has been 
demonstrated in simian immunodeficiency virus (SIV)-infected 
macaques(25). 
7. HIV may also directly impair HDL metabolism, thus enhancing transfer 
of HDL to atherogenic apolipoprotein B lipoproteins (26). This potential 
mechanism is consistent with findings in the recent SMART trial analysis 
indicating an association of total HDL particles with risk of CVD in 
patients in the drug-conservation group (27). In particular, risk was 
elevated in patients with declining HDL cholesterol levels 
Collectively, these findings suggest that untreated HIV infection could 
contribute to the development of atherosclerosis, although the magnitude of the 
effects remains unclear.  
  
Figure 2 Interaction of host, virus, and antiretroviral therapy effects in cardiovascular 
disease risk 
 
Another mechanism by which HIV infection itself may contribute to CVD 
risk is inflammation. CRP is a marker of inflammation that independently 
predicts risk of CVD in adults in the general population. In HIV infection, 
elevated CRP levels predict HIV disease progression and mortality in untreated 
HIV patients after adjustment for viral load and CD4+ count. Uncontrolled HIV 
infection is associated with elevated markers of inflammation, including CRP. 
Levels of these markers decline with treatment but not to normal levels. Little is 
known about how different antiretroviral drugs affect CRP levels during 
successful anti retroviral therapy. Recent data from ACTG (AIDS Clinical 
Trials Group) study 5095 demonstrated that CRP levels did not improve during 
96 weeks of treatment with efavirenz; in fact, among women CRP levels rose 
(28)
. Elevated baseline levels of the inflammatory marker interleukin-6 (IL-6) 
and the coagulation marker D-dimer were associated with all-cause mortality 
(not specifically with CVD events) in the SMART trial, and levels of these 
markers rose after treatment interruption (29).Despite the potential association of 
inflammation with increased CVD risk, a number of small studies have not 
found a strong association between higher levels of high-sensitivity CRP 
(hsCRP) and IMT. Hsue and colleagues found no association of hsCRP or 
immune activation (CD38+, CD4+, CD8+ cell responses) with IMT, but they 
reported an association between IMT and cytomegalovirus-specific T-cell 
responses, suggesting that response to latent or persistent viral infection might 
be driving a pro-atherosclerotic response (30). Other findings include improved 
endothelial function (measured by brachial artery reactivity) after 24 weeks of 
antiretroviral therapy in treatment-naïve patients but no significant change in 
hsCRP level. In a pilot study in patients with untreated HIV infection, 8 weeks 
of treatment with the tumour necrosis factor inhibitor pentoxifylline resulted in 
improvements in the endothelial activation marker VCAM-1 and brachial artery 
flow-mediated dilation(31).The effects of such an approach to reducing 
inflammation in antiretroviral therapy–treated patients with viral suppression 
are being investigated. 
Antiretroviral Therapy Factors 
Recent studies showed that the risk of MI increases by 26% per year of 
HAART in HIV patients when compared to the non-HIV patients. 
Endothelial Dysfunction In ART Therapy 
Endothelial dysfunction, a likely precursor of early atherosclerosis, has 
been reported in HAART-naive patients and in patients treated with PIs and 
nucleoside reverse transcriptase inhibitors (NRTIs). Similarly, HAART-
mediated endothelial dysfunction has been attributed to a reduction in nitric 
oxide production or release(32), and an increase in reactive oxygen species 
production (33, 34), as well as impairment of cholesterol efflux and accelerated 
foam cell formation (35, 36).  
Lipid And Metabolic Abnormalities In ART Therapy 
The etiology and development of the dyslipidaemic, anthropometric and 
metabolic changes observed in chronically HIV-infected patients and its 
interplay with enhanced CVD risk is complex (37). These changes often coexist 
and are modulated by therapy with HAART, genetic and dietary factors and 
together appear to exert synergistic atherogenic effects on the vasculature. 
Lipid abnormalities are characterised by low levels of high-density 
lipoprotein (HDL) and LDL cholesterol and high levels of very low-density 
lipoprotein (VLDL) and triglycerides (37, 38). Overall, this lipid milieu may be 
atherogenic due to low HDL levels and an increase in de novo lipogenesis and 
reduced VLDL clearance (39). Various PIs, in particular ritonavir, can cause 
hypertriglyceridaemia (40) while other agents increase LDL modestly (41). Carr et 
al  hypothesised that the catalytic region of HIV-1 protease (the binding site of 
various PIs) possesses some homology to regions of proteins regulating lipid 
metabolism (cytoplasmic retinoic acid-binding protein-I and LDL receptor-
related protein) so that PI binding to these proteins results in impaired hepatic 
chylomicron uptake and triglyceride clearance by LDL receptor-related protein-
lipoprotein-lipase complex (42, 43). Other mechanisms of PI-induced 
dyslipidaemia have been described and include inhibition of Apo-B degradation 
(44)
. 
With the advent of HAART, anthropometric changes in HAART-naive 
patients were observed following NRTI and PI treatment, which were 
characterised by early increases in subcutaneous and visceral fat followed by 
loss of subcutaneous fat (peripheral lipoatrophy) with relative preservation of 
visceral fat (visceral adiposity) (42, 45, 46). Such lipodystrophic changes have been 
reported in 30-50% of HAART users (particularly with stavudine and 
didanosine or zidovudine and lamivudine combined with nelfinavir, efavirenz, 
or both) (47, 48) while up to 26% of HIV-infected patients can be diagnosed with 
metabolic syndrome (49, 50). The pathogenesis of HAART-induced lipodystrophic 
changes is complex (37) and may involve mitochondrial toxicity (51) and 
modulation of adipocyte differentiation (52). Visceral fat accumulation is a pro-
inflammatory state because visceral adipose tissue produces and secretes 
proinflammatory cytokines (TNF-[alpha], IL-6, MCP-1) and adipokines 
(adiponectin, leptin and resistin) that attract and recruit macrophages to adipose 
tissue, stimulate hepatic CRP production and exacerbate insulin resistance (49,53). 
Once activated, macrophages elaborate further proinflammatory mediators 
continually driving chronic vascular inflammation (49). 
Metabolic changes, in particular insulin resistance, may result from the 
developing anthropometric changes as well as from the direct effects of 
HAART(54). Diabetes mellitus has been reported to occur in 6-18% of HIV-
infected patients(54) whilst the prevalence of insulin resistance may be as high as 
50% in those with anthropometric abnormalities (55). PIs and NRTIs have been 
most frequently implicated via selectively inhibiting the transport function of 
Glut 4 receptor (56) and inhibiting mitochondrial function in skeletal muscles (57), 
respectively. 
  
Cholesterol Efflux Impairment In HIV Patients 
Accumulation of oxidised LDL cholesterol in macrophages due to 
unregulated uptake by CD36 scavenger receptors leads to foam cell formation. 
There is evidence that PIs can upregulate the macrophage CD36 scavenger 
receptors to promote cholesterol ester accumulation (35, 36, 49). 
In the current HAART era, PI-based regimens are common and have been 
associated with elevations in VLDL and LDL levels (58-60), which may translate 
into greater clinical risk of CVD. More recently, we have shown that HIV itself, 
rather than the commonly used antiretroviral compounds (stavudine, efavirenz, 
nevirapine, lopinavir, amprenavir, nelfinavir and ritonavir), impairs cholesterol 
efflux (61). This implies that HAART promotes atherosclerosis mainly by 
enhancing forward cholesterol transport and delivery of LDL and oxidised LDL 
to macrophages, while HIV appears responsible for the inhibition of reverse 
cholesterol transport. 
Protease inhibitors (PIs) may influence lipid metabolism by interfering 
with the degradation by proteasomes in hepatocytes and adipocytes, thus 
influencing the expression of genes involved in lipid metabolism. Genes 
involved in lipid synthesis were also upregulated in hepatocytes by lopinavir, 
ritonavir, and nelfinavir, but repressed in adipocytes, consistent with the 
observations in vivo of increased hepatic lipid synthesis but reduced storage in 
fat cells. Inhibition of proteasomes in vivo with the resultant impact on lipid 
biosynthesis may be the etiology of PI-associated dyslipidaemia, and the 
absence of an effect of atazanavir on these pathways may explain the absence of 
dyslipidaemia seen with this drug in vitro (62). 
There is also great interest in the role of adiponectin, a hormone secreted 
by adipocytes, in the pathogenesis of body composition changes observed 
during treatment of HIV infection. Cross-sectional studies have demonstrated 
reduced circulating levels of adiponectin in patients with both lipoatrophy and 
lipohypertrophy (62). In HIV patients, the mitochondrial and peroxisome 
proliferator-activated receptor-γ (PPAR–γ) gene expression decreased 
significantly (62). Among those on antiretroviral therapy, use of a non nucleoside 
reverse transcriptase inhibitor (NNRTI) was associated with higher HDL-c (63). 
Nucleoside reverse transcriptase inhibitors (NRTIs) act via their 
incorporation into the growing viral DNA chain during reverse transcription, 
with incorporation resulting in chain termination. The NRTIs also inhibit 
gamma polymerase in vitro, and thus inhibit mtDNA synthesis. Consequent 
mtDNA depletion (or mutation) can result in insufficient energy production and 
cell dysfunction and in tissue and organ dysfunction when sufficient numbers of 
normally functioning mitochondria are not present (64). In addition to the 
potential effects of gamma polymerase inhibition, NRTIs may also be 
associated with oxidative damage to mitochondria (65), inhibition of 
mitochondrial enzymes (66), uncoupling of the electron transport chain from 
ATP (Adenosine triphosphate) synthesis, and induction of apoptosis(67). 
Complications of NRTIs include cardiomyopathy, myopathy, peripheral 
neuropathy, pancreatitis, proximal renal tubular dysfunction, and hepatic 
steatosis and lactic acidosis. Many of the effects associated with mitochondrial 
toxicity are difficult to distinguish from effects associated with HIV infection 
itself.  The phenotype of lipoatrophy in HIVinfected patients receiving 
antiretroviral therapy at least superficially resembles that in Madelung's disease 
(multiple symmetric lipomatosis), which is associated with mtDNA mutations. 
It has been hypothesized that mitochondrial toxicity of adipocytes associated 
with antiretroviral therapy may lead to adipocyte apoptosis and thus lipoatrophy 
(68, 69)
. Some support for this hypothesis is provided by the following findings 
from studies in patients receiving therapy: an association of lipoatrophy with 
hyperlactatemia and liver dysfunction in a patient series (70); abnormal adipocyte 
mitochondria on fat biopsies in a small number of patients with lipoatrophy (71); 
a 60% frequency of decreased mtDNA levels in subcutaneous fat biopsies 
(neck, abdomen, thigh) in patients with lipodystrophy versus a frequency of 0% 
to 30% in patients without lipodystrophy or in HIV-seronegative subjects (72); 
and the association of NRTI use with a decrease in mtDNA (mean, 44%) in fat 
biopsies in buttocks (73). In conclusion, accelerated atherosclerosis in ART 
therapy is multifactorial. 
LIMITATIONS OF THE STUDY 
• Limitations of our study include the use of cross-sectional data for both risk 
factors and cIMT. Given that the effects of HIV and antiretroviral therapy 
on CVD risk factors are dynamic and cumulative, it might have been ideal 
to have longitudinal data for risk factors.  
• Sample size is smaller.  
• Findings of this study cannot be extrapolated outside the adult population 
because our subjects were aged from 30 to 46 years. 
• We have also not included the post menopausal women in this study, so the 
influence of the post-menopausal state was left untouched. 
DISCUSSION 
We have shown that preclinical atherosclerosis as quantified by carotid 
Doppler ultrasound measurements of carotid IMT is increased in HIV-infected 
participants compared with controls, even after adjusting for demographic 
profiles and traditional CVD risk factors (gender, age, smoking, diabetes, and 
hypertension). This result correlate with the cross sectional study done by 
Grunfeld et al(75). In that study 1183 HIV infected participants and 297 HIV 
uninfected controls (from the FRAM study and MESA study) were studied from 
2000 to 2002. This study clearly codes that association between HIV infection 
and IMT was similar to that of the traditional risk factors like smoking.  
In the total of 182 individuals studied, HIV naïve, as well as the HIV 
positives on ART both had higher level of carotid IMT when comparing to 
matched control group. The three groups were well matched in the demographic 
profiles and traditional cardiovascular risk factors. There were no differences in 
the waist circumferences, waist/hip ratio. The control group had higher BMI 
values when compared to HIV positives (group 2 & 3). This is in contrast to the 
study done by Maggi et al (76), in which the BMI values and waist circumference 
were higher in the individuals on ART therapy. But Maggi et al study had 
patients, who are on long duration protease inhibitor therapy and significant 
body fat redistributions.  
The three groups had no differences in the total cholesterol levels, LDL 
cholesterol levels, HDL cholesterol levels. But M. Bongiovanni et al(77) study 
showed that the total cholesterol levels were lower in the control group when 
compared to HIV seropositive groups. Among the seropositive individuals, HIV 
patients on HAART therapy had significantly higher total cholesterol levels 
than HIV naïve patients. Rose et al (78) showed that the HDL levels are lower in 
the HIV affected patient. But in this study, there are no differences in the HDL 
levels between the groups. This can be explained by the patients on ART 
therapy in this study were on non protease inhibitor based regimen (zidovudine 
+ lamivudine and nevirapine). The NNRTI- nevirapine is the one drug which is 
shown to increase the HDL levels as described by Franssen et al (79). 
HIV seropositive groups had higher levels of triglycerides, which was 
more in the HIV naïve patients than who are on ART. This results correlate with 
the results from the Grunfeld et al study (80). This shows that HIV infection per 
se has effects on lipid metabolism in addition to chronic inflammation 
secondary to HIV, and due to ART therapy.  
In this study distribution of smokers were equal in all the three groups. But 
in the Massachusetts hospitals databases the prevalence of the smoking and 
alcoholism were high in the HIV affected individuals. Smokers had higher 
carotid IMT levels than non-smokers. Among the HIV infected individuals, the 
smokers had higher carotid IMT than non smoker HIV seropositives. 
Atheromatous plaque was identified in 16 individuals. There were no 
differences in the distribution of atheromatous plaques between the groups but 
the smokers had higher prevalence of plaques, which was statistically 
significant. 
Carotid IMT values were higher in males than females. This results 
correlates with the study by Alessandra vigano et al in which male adolescents 
and young adults had higher carotid IMT values than matched females (81). This 
may simply reflect the tendency of males to have higher values of IMT than 
females as described by Lee et al (82). In the study done by Grunfeld et al (83), the 
HIV association with IMT was somewhat stronger among women than in men 
(HIV by gender interactions for men p = 0.046 and for women p = 0.003). But 
in our study the HIV association with IMT was equal in males and females (p 
value for males & females were <0.001).  In our study we found that the CD4 
count had negative correlation with the carotid IMT values. In a study done by 
Priscilla et al (84), they identified that the CD4 count had inverse relationship 
with the carotid IMT levels. The CD4 count has inverse relation with the HIV 
viral load. Drop in CD4 count indirectly indicates the increasing viral load and 
hence the disease progression. So the increased inflammation and the HIV virus 
itself (by infecting the vascular smooth muscles, acceleration of foam cell 
formation, and impaired cholesterol efflux from the macrophages) could 
contribute in the accelerated atherosclerosis. These effects of inflammation and 
virus in the accelerated atherosclerosis were studied by Mujawar et al (85) and 
Bukrinsky et al (86).  
The HDL cholesterol levels also had inverse relationship with the carotid 
IMT values in HIV patients. This results correlates with the Rose et al study (87), 
in their study they proposed that the HIV may directly impair the HDL 
metabolism by enhancing the transfer of HDL to ApoB lipoprotein. Duprez et al 
(88)
 described that the decreasing HDL levels in HIV patients associated with 
increasing risk for cardiovascular diseases. 
We did the correlation analysis of predictive factors versus the carotid 
IMT. The results showed that the age, gender, waist circumference, triglyceride 
levels, LDL cholesterol levels and the duration of the disease were shown to 
have direct correlation with the carotid IMT levels. Of these, the age and gender 
had the strongest impact over the carotid IMT values. In this study, it is shown 
that the HIV status has more impact than the smoking status on the carotid IMT 
values. HIV naïve patients and HIV seropositives on ART therapy had no 
significant difference in the triglyceride levels or in carotid IMT values. But in 
the studies done by currier et al (89), and jerico et al (90), patients on ART therapy 
had significant increase in the cholesterol, triglyceride levels and also in IMT 
values. In contrary to this, the duration of ART therapy was negatively 
correlated with the IMT values of our study. The probable explanation is, we 
took only the patients who are on two NRTIs (zidovudine and lamivudine) and 
one NNRTI (nevirapine) regimen. Moreover in Currier et al and Jerico et al 
studies, most of the patients were on protease inhibitors containing regimen and 
also they were not on NNRTI; and the treatment duration was significantly 
higher than our study.  
After multivariate regression adjustment for demographic characteristics (age, 
gender), the adjusted mean difference of HIV-infected vs controls was +0.04 
mm (p <0.0001). Further adjustment for traditional CVD risk factors (smoking, 
elevated triglycerides, BMI, total cholesterol, LDL and HDL cholesterol) 
modestly attenuated the HIV effect (+0.036 mm, p<0.001).This shows that, the 
HIV infection was independently associated with greater IMT. The association 
of HIV infection with IMT was more than that of traditional risk factors such as 
smoking which was associated with greater IMT (+0.011 mm, p<0.001). 
Moreover the duration of the disease positively correlated to the higher IMT 
values. This is supported by the study done by the study done by Mercie et al 
(91)
. 
MATERIALS AND METHODS 
Settings  
ART CENTRE,  
Institute of internal medicine and Barnard institute of radiology,  
Madras Medical College and Government General Hospital,  




This study was conducted for a period of eighteen months from January 
2009 to June 2010. 
Study Design 
To predict the impact of HIV infection and antiretroviral therapy on the 
development of subclinical atherosclerosis by carotid intimal medial thickness, 




1. Patients with HIV infection and not on any antiretroviral therapy 
(Duration of disease > 2 years). 
2. Patients with HIV infection and on antiretroviral therapy with the 
duration of >than 2 years (ZIDOVUDINE + LAMIVUDINE + 
NEVIRAPINE regimen).  
3. Normal HIV unaffected individuals as controls 
Exclusion Criteria 
1. Patients with diabetes mellitus or current use of oral hypoglycaemic 
agents and/or Thiazolidinediones, 
2. History of coronary heart disease or stroke. 
3. Hypertension, endocrine disorders. 
4. Family history of coronary heart diseases, stroke.Hypercholesterolemia.  
5. Obesity [defined as a body mass index (BMI) > 30]. 
6. Subjects with abnormal renal or liver parameters [creatinine >1.6mg/dl; 
alanine aminotransferase or aspartate aminotransferase > 2.5 × upper 
limit of normal (ULN)]. 
7. Subjects requiring systemic chemotherapy, radiation therapy or systemic 
Steroids were excluded. 
8. Patients having active opportunistic infections. 
9. Patients with HBV and HCV infections. 
10. Patients with CD4 count less than 250. 
11. Patients with poor adherence to therapy. 
12. Female patients with post menopausal state. 
13. Patients on statins or anti-inflammatory drug therapy 
Laboratory Methods  
All patients with HIV referred to ART centre were subjected to a detailed 
clinical history regarding their age, occupation, socio economic status, 
educational status, possible route of acquisition of the disease, duration of 
disease, duration of ART(if any), marital status, history of opportunistic 
infections, sexually transmitted infections, previous HIV testing,  
medication/drug  use, co morbidities like diabetes, hypertension, hepatitis B/C, 
history of vaccination,  allergy,  history regarding diet, smoking/alcoholism and 
family history regarding CVD risk factors. A complete physical examination 
was performed, including the measurement of blood pressure (determined by 
using a sphygmomanometer with the subjects in a sitting position after >30 min 
at rest) and the calculation of body mass index (BMI), Waist/Hip ratio. 
Initial investigations included complete blood count, renal function tests, 
liver function tests, CD4 count. Blood was taken in a fasting state (>8 hrs of 
fasting) to test for blood sugar, total cholesterol, serum triglycerides, HDL-
cholesterol, LDL-cholesterol concentration was calculated by the Friedewald 
formula (74). CD4+ cell counts using the PARTEC flow cytometer (Germany). 
All subjects underwent an ultrasonography of the carotid vessels using the   
ESAOTE (my lab 60) colour-Doppler with 7.5 MHz (LA 523) high frequency 
probes. Characteristics of the intima, pulsation index, resistance index, minimal 
speed, peak speed and mean speed were evaluated. All the ultrasonographies 
were performed by the same sonologist, who was unaware of the HIV status, 
with the same colour power Doppler. Patients were submitted to the 
investigation in a supine position after at least 10 min of acclimatization in a 
comfortable room. During the examination, the head of the patient was extra-
rotated from the opposite side. Once the image had been optimized, the 
bifurcations of the vessels were located and the echocardiograph zoom was 
deployed. The common carotid, the bifurcation and at least the first 2 cm of the 
internal and external carotid vessels were examined in the short and long axis 
during the tele-diastolic phase (T wave of the electrocardiogram). Carotid IMT 
was measured between the bifurcation and 1 cm proximal to the bifurcation 
(near the bulb). The same procedures were then repeated for the opposite side 
carotid vessels. Then the averages of two measurements were taken IMT as 
final reading.  
  
METHODS 
Study subjects are divided into three groups: group 1, group 2, and 
 group 3. 
Group 1 
 HIV-uninfected control subjects. They were selected from the patient’s 
relatives from the internal medicine wards.  
Group 2  
HIV-infected subjects, who are having the disease more than 2 years. Not 
yet started on ART therapy (defined as not receiving any regimen for more than 
a total of 3 months at any time prior to study entry).  
Group 3  
HIV-infected subjects who were currently receiving antiretroviral therapy 
(ZIDOVUDINE + LAMIVUDINE + NEVIRAPINE regimen). The subjects 
must have taken the treatment at least 2 years or more, continuous use prior to 
study. Interruptions in therapy for at most 4 weeks for management of toxicity 
was allowed. 
Subjects from each group, were matched on five cardiovascular disease 
risk factors: age (within 5 years), sex, and smoking status (yes or no), and 
menopausal status. The matched design was employed in order to control for 
important traditional risk factors for atherosclerosis while attempting to isolate 
the effects of HIV infection and ART therapy on carotid IMT. 
Study Population: 
A total of 121 patients were enrolled for the study from the population of 
HIV infected patients who attended the ART clinic, Institute of Internal 
Medicine, from the period between January 2009 and June 2010. In which 64 
were HIV naïve patients and remaining 57 are HIV patients on ART therapy. 
Controls (61 volunteers) for the study were selected from the internal 
medicine wards, who came with the patients. Only who satisfied all the 
inclusion and exclusion criteria, were included for the study. Informed written 
consent was obtained from all patients participating in the study. 
  
Statistical Analysis: 
Data analysis was done with use of SPSS, version 15. Descriptive statistics 
were used to calculate the frequency, mean, median, and standard deviation. To 
examine the linear trend of the proportions, trend chi-square was used and to 
find the test of association, chi-square was computed. For all normally 
distributed variables, Student’s t test was used to determine the significant mean 
difference in various groups. Multivariate regression analyses were performed 
to find potential predictors of carotid intimal thickening. The covariates 
considered for all subjects were: gender, age, smoking habit, BMI, waist 
circumference, waist hip ratio, triglycerides, total cholesterol, LDL, HDL. For 
the HIV-infected subjects, additional covariates included were duration of the 
disease, length of ART use (in months) and CD4 cell count (× 106 cells/l). The 
results of the univariate analysis were used as a guide for the multivariate 
analysis. The primary hypothesis was to investigate the difference in carotid 
IMT between groups. The planned comparison of group 1 to group 2+3 was to 
assess the effect of HIV infection on carotid IMT. The planned comparison of 
group 2with group 3 was to assess the effect of ART therapy on carotid IMT in 
the HIV-infected subjects.   
 
OBSERVATION AND RESULTS
A total of 182 patients were studied. In which, controls were taken as 
group 1, HIV naive patients were taken as group 2, HIV patients who are on 
ART were considered as group 3. Females were 65(35.7%). Mean age was 38 
years (30-46). For both age and sex, t
(p>0.05). The details of the age and sex distribution among groups are given 
below. 
Figure 1 Percentage of individuals in each group.
Table 1 Percentage of individuals in each group.
Groups 
Control 
HIV without ART 





here were no differences between groups 
 
 












Figure 2 Age distribution among the groups. 
 
Table 2 Age comparison between groups. 
Group Mean age Std. Deviation p value 
Control 38(30-46) 5.116 
0.06 
HIV without ART 37(30-46) 4.817 
HIV with ART 39.3(30-45) 4.702 
Total 38(30-46) 4.96 
Mean age among controls was 38 years with the standard deviation of 
5.116, in HIV naive patients it was 37(SD: 4.817), and the mean age in HIV 
patients on ART was 39.3 (SD:4.702). Males were dominated in the sex 
distribution with 64.3%. There were no statistically significant difference 














































 37 24 61 
 60.7% 39.3% 100% 
 31.6% 36.9% 33.5% 
 43 21 64 
 67.2% 32.8% 100% 
 36.8% 32.3% 35.2% 
 37 20 57 
 64.9% 35.1% 100% 
 31.6% 30.8% 31.3% 
 117 65 182 
 64.3% 35.7% 100% 
 100% 100% 100% 







Figure 4 Distribution of smokers overall and within the groups.


















In the control group, 21.3% were smokers, group 2, and group 3 had smokers of 












 13 48 61 
 21.3% 78.7% 100% 
 32.2% 33.3% 33.5% 
 13 51 64 
 20.3% 79.7% 100% 
 34.2% 35.4% 35.2% 
 12 45 57 
 21.1% 78.9% 100% 
 31.6% 31.3% 31.3% 
 38 144 182 
 20.9% 79.1% 100% 


















Figure 5 BMI differences between groups. 
 
Table 5 Comparison of the BMI between groups. 






Control 61 20.99175 1.430901 
<0.001 
HIV without 
ART 64 20.27362 1.018532 
HIV with ART 57 20.40400 0.845831 
Total 182 20.55514 1.166456 
  







In HIV patients, average duration of disease was 40.1months (29-
55months) with 39.6 months in HIV naives and 40.6 months in HIV patients on 
ART. The mean duration of ART treatment was 35.1 months (29-41months) in 
group 3. Mean BMI in HIV naive patients, was 20.27(SD: 1.02), and in HIV 
patients on ART, it was 20.4 (SD: 0.846). Controls had little bit higher BMI 
score (mean: 21; SD: 1.43), than HIV patients (group 2+3) (mean: 20.33; SD: 
0.94). The difference was significant (p<0.001).  
The mean Hb level in controls was 11.7gm/dl, for HIV patients it was 
10.3gm/dl. When compared with controls (group 1), HIV patients (group 2+3) 
had significant differences in the haemoglobin levels (p<0.001). 
Significant differences also noted in serum protein levels (controls: mean-
7.24gm/dl; HIV positive-6.8gm/dl: p<0.001), serum albumin levels 
(controls:4.1gm/dl; HIV positive-3.8gm/dl: p<0.001). 
  
Table 6 Differences in the haemoglobin, protein, albumin levels between groups. 








Control 61 11.687 1.3239 
<0.001 
HIV naive 64 10.163 1.2053 
HIV on ART 57 10.475 1.2633 
Total 182 10.771 1.4218 
Total Protein 
Control 61 7.246 0.2884 
<0.001 
HIV naive 64 6.795 0.4513 
HIV on ART 57 6.954 0.3157 
Total 182 6.996 0.4064 
Albumin 
Control 61 4.113 0.2711 
<0.001 
HIV naive 64 3.766 0.3591 
HIV on ART 57 3.867 0.2552 
Total 182 3.914 0.3335 
  
Differences In The HDL Levels Between Groups: 
 
The mean serum HDL cholesterol level in controls was 51 mg/dl. In HIV 
naïve patients, it was 47.8 mg/dl, and in HIV patients with ART, it was 48 
mg/dl. There were no statistically significant differences between the groups. 
No associations were found between the serum HDL levels and the CD4 count 
or duration of ART therapy. But there was a negative association found between 
the serum HDL cholesterol levels and the carotid intimal medial thickness 
levels. The Pearson correlation score was -0.387 with the 2-tailed significance 
of <0.001. 
Figure 6 Comparison of HDL cholesterol levels between groups. 
 
Table 7 Comparing HDL levels among groups. 
Groups Mean HDL (mg/dl) Minimum Maximum 
Significance 
(p value) 
Control 51 39 62 
0.081 
HIV naive 47.8 40 58 
HIV on ART 48 36 58 









Control HIV naïve HIV on ART
HDL (mg/dl)
Figure 7 Differences in the triglyceride levels among groups.







HIV patients had higher level of triglyceride levels when compared with 
controls. Among the HIV patients, when compared to HIV naives, patients on 




















61 108.74 11.897 
64 118.17 13.389 
 57 114.68 14.681 
182 113.92 13.842 
 





No correlation was found between the total cholesterol, and the IMT 
levels. In the waist circumference, controls had a mean of 66.9cm, HIV naive 
65.75cm, and in HIV with ART 65.9cm: there were no significant differences 
between groups. 
Table 9 Comparing the differences between the LDL, total cholesterol, fasting 
blood sugar, waist circumference between groups. 




Control 61 66.89 5.648 
.444 HIV naive 64 65.75 4.458 
HIV on 
ART 57 66.14 4.930 
W/H ratio 
Control 61 .8361 .05315 
.624 HIV naive 64 .8404 .04949 
HIV on 
ART 57 .8311 .05517 
FBS 
Control 61 87.41 7.152 
.548 HIV naive 64 88.84 7.901 
HIV on 
ART 57 87.70 8.073 
Total 
cholesterol 
Control 61 168.44 14.627 
.702 HIV naive 64 169.44 13.015 
HIV on 
ART 57 167.33 13.470 
LDL 
Control 61 95.662 11.5722 
.347 HIV naive 64 97.991 10.4524 
HIV on 
ART 57 98.046 8.4519 
  
Carotid IMT Measurements:
The mean maximal IMT (Carotid intimal medial thickness) was 0.726 mm 
for HIV-infected subjects, with standard deviation of 0.0189. For controls, the 
IMT was 0.686mm with standard deviation of 0.0208. Mean difference between 
HIV-infected vs controls was +0.
Figure 8 Picture showing the differences in the carotid IMT levels between the 
Table 10 Comparing the carotid IMT values between the groups.




HIV on ART 57
The median IMT in group 1, group 2, and group 3 was 0.686, 0.727 and 
















 0.68634 0.020857 
 0.72718 0.020801 
 0.72431 0.016523 
 
HIV naïve HIV on ART






Carotid Intimal Thickness Differences Between The Men And Women:
The mean maximal carotid intimal thickness in males was 0.724 mm with 
standard deviation of 0.0231 and in females 0.692mm with standard deviation 
of 0.0205. Mean difference between males and 
0.0257 to 0.0391). 
Figure 9 Picture comparing the differences in the carotid IMT between males and 
Table 11 Comparison of carotid IMT between males and females. Males had higher 




















Mean SD Std.error 
of mean 
Significance 
0.724 0.023 0.0021 






Correlation Between Smoking And Carotid IMT:
Figure 10 Picture comparing carotid IMT differences between smokers and non
Compare to non-smokers, smokers had higher IMT values which was 
statistically significant. In the HIV positive individuals, the IMT values were 
higher among smokers. 
Table 12 Comparison of IMT values between smokers and non


































smokers of each group. 








 13 0.7073 
 48 0.686 
 13 0.7476 
 51 0.7270 
 12 0.7405 
 45 0.7250 











Groups And Atheromatous Plaque:  
There were no significant differences in the distribution of Atheromatous 
plaques between the groups. The distribution of Atheromatous plaque were not 
increased in the HIV patients and it was also not significantly related ART 
therapy (p >0.05). Smokers had higher prevalence of atheromatous plaques 
when compared to non-smokers. 




Plaque Total P value 
Yes No 
Control 
Count 4 57 61 
0.688 




25.0% 34.3% 33.5% 
HIV naive 
Count 7 57 64 
.685 




43.8% 34.3% 35.2% 
HIV on ART 
Count 5 52 57 
.661 




31.3% 31.3% 31.3% 
Total 
Count 16 166 182 
 
% within group 8.8% 91.2% 100.0% 
  
Distribution Of Atheromatous Plaque (Over All and Between Groups):
Figure 11 Figures showing the distribution of plaques in the total study population and 


























Correlation And Regression Analysis: 
The multivariate linear regression models were used to assess how well the 
Baseline covariates individually predict carotid IMT on the 182 subjects with 
Carotid IMT data. Regression analysis showed that the factors related to the 
carotid IMT were age, male sex, smoking, triglycerides, and HIV status 
(significance of <0.001 for all); and the standardized coefficients (beta) were 
orderly 0.152, 4.82, 0.169, 0.181, 0.624. This shows that the HIV status is 
independently associated with carotid IMT values. The impact was more than 
that of smoking. 
Even after adjusting for traditional cardio vascular risk factors, the 
association between HIV and carotid IMT was still significant (P<0.001). 
Carotid IMT levels between the HIV naives and HIV patients on ART had a 
difference of 0.003mm which was not statistically significant. The correlation 
analysis showed that waist circumference (+0.27), triglycerides (+0.358), LDL 
levels (0.256), duration of the disease (+0.260), age (+0.318) are all directly 
correlated to the carotid IMT values (p<0.001). 
The total CD4 counts were negatively correlated (-0.199) to the IMT 
values. Patients with lower CD4 counts had higher IMT values when compared 
to their matched ones. Likewise the HDL cholesterol levels were also had 
negative correlation (-0.387) with the IMT values (p<0.001). 
  
Table 14 Table showing the multivariate regression analysis of independent variables of 










Constant 0.651 0.041  <0.001 
Age in year 0.001 0.000 0.152 <0.001 
Male Sex 0.027 0.005 0.482 <0.001 
HIV status 0.036 0.003 0.624 <0.001 
BMI Index 0.001 0.001 0.038 0.492 
Waist circumference 0.000 0.000 0.040 0.442 
W/H ratio -0.015 0.046 -0.029 0.744 
Smoking 0.011 0.002 0.169 <0.001 
Tri Glycerides 0.000 0.000 0.181 <0.001 
LDL -1.519E-05 0.000 -0.006 0.888 
HDL 0.000 0.000 0.063 0.104 
*Carotid IMT: A Dependent Variable  
 
Total cholesterol levels were not correlated well with the carotid IMT 
levels of study groups. There was no significance in the statistical analysis 
while comparing the total cholesterol level and the carotid IMTs of controls, 
and HIV patients with or without ART. 
  
Correlation Between IMT And Variables: 
Figure 12 Picture showing the strength of correlation of variables with the carotid IMT. 
 
Positive Correlations: 
1. Age (o.318) 
2. Waist circumference (0.27) 
3. Plasma triglyceride levels (0.358) 
4. LDL cholesterol levels (0.256) 
5. Duration of disease (0.26) 
Negative Correlations: 
1. HDL cholesterol levels (-0.387) 
2. CD4 counts (-0.199) 




















Pearson correlation between IMT and variables
Figure 13 Graph showing the correlation of carotid IMT with the CD4 count.
CD4 count has inverse 
in the picture, the linear IMT values decreases when the CD4 count falls. This 
reflects the direct correlation of carotid IMT with the increasing viral load.
Figure 14 Graph showing the correlation of carotid IMT with the duration of HIV 
Likewise carotid IMT is directly correlated duration of disease. As the 
duration of disease increases, the linear carotid IMT value goes up.
  







Table 15 Pearson’s correlation table for carotid IMT with independent variables. 





(p value; 2 tailed) 
Waist circumference 182 0.270(**) 0.000 
FBS 182 0.026 0.729 
Total cholesterol 182 0.115 0.121 
Tri Glycerides 182 0.358(**) 0.000 
LDL 182 0.256(**) 0.000 
HDL 182 -0.387(**) 0.000 
CD4 count 121 -0.199(*) .029 
Duration of disease 
(months) 121 0.260(**) 0.004 
Duration of Treatment 
(months) 57 -0.019 0.890 
Age (years) 182 0.318(**) 0.000 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
 
CONCLUSION 
• Even after adjustment for traditional CVD risk factors, HIV infected 
patients had higher subclinical atherosclerosis measured by IMT.  The 
association of HIV infection with IMT was similar to that of traditional 
CVD risk factors, such as smoking. These effects could be due to chronic 
inflammation of the disease and the HIV virus per se. 
• This accelerated progression could increase the incidence of CVD 
morbidities and mortalities among the HIV seropositives compared to 
HIV seronegatives. 
• In our study NNRTIs and NRTIs based ART regimen not shown to have 
significant impact on subclinical atherosclerosis. But the correlations 
were on the negative side. This shows that the ART therapy may retard 
the progression of atherosclerosis in HIV patients. 
• Monitoring for traditional risk factors, steps to modify risk factors such as 
smoking is very important in HIV seropositive individuals. 
• CD4 counts are inversely related to the progression of atherosclerosis. 
• Periodical monitoring of lipid abnormalities and efforts to control other 
risk factors are mandatory in the prevention of ART related 
cardiovascular complications. 
• Our study encodes for the requirement of large volume, longitudinal 
follow-up studies to reveal the causal relationship of HIV effect and 
atherosclerosis. 
• Use of lipid lowering drugs, the role of NNRTIs in the reduction of lipid 
abnormalities in HIV patients has to be further studied. 
 
